A small, phase II study presented at the ASCO 2020 Virtual Scientific Program found that avelumab (Bavencio) demonstrated the potential to cure 53% of patients with gestational trophoblastic tumors (GTT) who were resistant to single-agent chemotherapy.
In an interview with CancerNetwork, lead study author Benoit You, MD, PhD of the Centre Hospitalier Lyon-Sud and Lyon Investigational Center for Treatments in Oncology and Hematology, discussed the study and some key results from it.
So, we enrolled 15 patients, out of them 8 patients had HCG normalization, and we could stop avelumab. And none of them presented any relapse after avelumab discontinuation, and we have now 29 months follow up, meaning these patients are likely to be cured from the GTT. So that means actually, we successfully treated 53% of the patient. Interestingly, out of these patients, where [they]…